Nimble Therapeutics is collaborating with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases.   The collaboration will leverage Nimble’s proprietary peptide synthesis, screening and optimization platform, chemical diversity, and integrated suite of assays to enable faster discovery and optimization of promising compounds for intracellular and extracellular targets.   “We are excited t...